Active • Host: E. coli • AA: 1,564-1,880 • Tag: N-terminal His • MW: 36.8 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV-2 Papain-like Protease (recombinant)

Item No. 31817

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • 2019-nCoV PLpro
  • COVID-19-PLpro
  • SARS-CoV-2 PLpro
  • Severe Acute Respiratory Syndrome Coronavirus 2 Papain-like Protease
Purity
≥90% estimated by SDS-PAGE
Source
Active recombinant SARS-CoV-2 N-terminal His-tagged papain-like protease expressed in E. coli
Amino Acids
1,564-1,880
MW
36.8 kDa
Formulation (Request formulation change)
Lyophilized from sterile 20 mM Tris, pH 7.4, with 500 mM sodium chloride
Specific Activity
>80 pmols/min/μg
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $543

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus and the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.1,2,3,4,5 The SARS-CoV-2 genome contains approximately 30 kilobases and 14 open reading frames (ORFs) that encode four structural proteins: spike, envelope, membrane, and nucleocapsid, as well as 16 non-structural proteins and 9 accessory factors.6 The SARS-CoV-2 papain-like protease (PLpro) is encoded within the non-structural protein 3 (nsp3) region of ORF1ab. It cleaves non-structural proteins 1-3, which, together with non-structural proteins 4-16, form the replicase complex. In addition, it reverses certain post-translational modifications, preferentially removing interferon-stimulated gene product 15 (ISG15), but also removing ubiquitin, from host proteins with both actions leading to suppression of the host innate immune response.7,8 SARS-CoV-2 PLpro decreases IFN-α-induced ISGylation of IFN regulatory factor 3 (IRF3) in A549 cells and inhibits the type I IFN response.8 Inhibition of SARS-CoV-2 PLpro activity reduces SARS-CoV-2 replication and viral particle release from infected cells in vitro and increases the level of IRF3 ISGylation. Cayman’s SARS-CoV-2 Papain-like Protease (recombinant) protein can be used for enzyme activity assays. This protein consists of 324 amino acids and has a calculated molecular weight of 36.8 kDa.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et al. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et al. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    4. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).

    5. Yang, F., Shi, S., Zhu, J., et al. Analysis of 92 deceased patients with COVID-19. J. Med. Virol. 92(11), 2511-2515 (2020).

    6. Romano, M., Ruggiero, A., Squeglia, F., et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9(5), 1267 (2020).

    7. Freitas, B.T., Durie, I.A., Murray, J., et al. Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease. ACS Infect. Dis. 6(8), 2099-2109 (2020).

    8. Shin, D., Mukherjee, R., Grewe, D., et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587(7835), 657-662 (2020).